文献速递腹部技术与安全CT

全自动腹部CT体成分测量预测结直肠癌患者生存

Utility of Fully Automated Body Composition Measures on Pretreatment Abdominal CT for Predicting Survival in Patients With Colorectal Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2022-08-24

该回顾性研究纳入1766例结直肠癌患者,利用全自动AI算法在治疗前腹部CT门静脉期图像上量化L3骨骼肌衰减、内脏脂肪面积、皮下脂肪面积及腹主动脉钙化。结果显示死亡患者肌肉衰减、皮下脂肪面积更低而主动脉钙化更高;肌肉衰减、皮下脂肪面积和主动脉钙化组合预测5年生存的AUC在无转移和有转移患者中分别为0.758和0.732。常规体成分评估有助于改善结直肠癌患者初始风险分层。

要点

  • 治疗前腹部CT全自动体成分测量可预测结直肠癌患者生存,组合肌肉衰减、皮下脂肪面积和主动脉钙化预测效能最佳。
  • 肌肉衰减最低四分位、皮下脂肪面积最低四分位和主动脉钙化最高四分位患者死亡风险增加。
  • BMI不能显著预测死亡,提示体成分指标优于传统BMI。

关键影像表现/征象

  • 死亡患者较存活者肌肉衰减更低(中位数19.2 HU vs 26.2 HU,p<.001)。
  • 死亡患者较存活者皮下脂肪面积更低(中位数168.4 cm² vs 197.6 cm²,p<.001)。
  • 死亡患者较存活者主动脉钙化积分更高(中位数620 vs 182,p<.001)。

诊断标准与关键数值

  • 无转移患者(n=1303)中,肌肉衰减预测5年生存AUC为0.666,主动脉钙化为0.677。
  • 有转移患者(n=463)中,肌肉衰减预测5年生存AUC为0.701,主动脉钙化为0.689。
  • 肌肉衰减、皮下脂肪面积和主动脉钙化组合预测5年生存AUC在无转移和有转移患者中分别为0.758和0.732。
  • 肌肉衰减最低四分位死亡风险增加(HR=1.55,p<.05);皮下脂肪面积最低四分位死亡风险增加(HR=1.81,p<.05);主动脉钙化最高四分位死亡风险增加(HR=1.37,p<.05);内脏脂肪面积最高四分位死亡风险降低(HR=0.79,p<.05);皮下脂肪面积最高四分位死亡风险降低(HR=0.76,p<.05)。
  • 在423例有BMI数据的患者中,BMI不能显著预测死亡(p=.75)。

临床应用与阅片要点

  • 治疗前腹部CT门静脉期图像可机会性用于全自动体成分分析,无需额外扫描或手动勾画。
  • 关注L3层面肌肉衰减、皮下脂肪面积和腹主动脉钙化,组合指标比单一指标预测效能更高。
  • BMI正常但肌肉衰减或皮下脂肪面积低的患者仍可能高风险,报告时可提示临床。

局限性

  • 单中心回顾性研究设计。
  • 仅纳入结直肠癌患者,结论外推需谨慎。
  • 体成分测量基于门静脉期图像和特定AI算法,不同设备或算法间可重复性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. CT examinations contain opportunistic body composition data with potential prognostic utility. Previous studies have primarily used manual or semiautomated tools to evaluate body composition in patients with colorectal cancer (CRC). OBJECTIVE. The purpose of this article is to assess the utility of fully automated body composition measures derived from pretreatment CT examinations in predicting survival in patients with CRC. METHODS. This retrospective study included 1766 patients (mean age, 63.7 ± 14.4 [SD] years; 862 men, 904 women) diagnosed with CRC between January 2001 and September 2020 who underwent pretreatment abdominal CT. A panel of fully automated artificial intelligence-based algorithms was applied to portal venous phase images to quantify skeletal muscle attenuation at the L3 lumbar level, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area at L3, and abdominal aorta Agatston score (aortic calcium). The electronic health record was reviewed to identify patients who died of any cause (n = 848). ROC analyses and logistic regression analyses were used to identify predictors of survival, with attention to highest- and lowest-risk quartiles. RESULTS. Patients who died, compared with patients who survived, had lower median muscle attenuation (19.2 vs 26.2 HU, p < .001), SAT area (168.4 cm2 vs 197.6 cm2, p < .001), and aortic calcium (620 vs 182, p < .001). Measures with highest 5-year AUCs for predicting survival in patients without (n = 1303) and with (n = 463) metastatic disease were muscle attenuation (0.666 and 0.701, respectively) and aortic calcium (0.677 and 0.689, respectively). A combination of muscle attenuation, SAT area, and aortic calcium yielded 5-year AUCs of 0.758 and 0.732 in patients without and with metastases, respectively. Risk of death was increased (p < .05) in patients in the lowest quartile for muscle attenuation (hazard ratio [HR] = 1.55) and SAT area (HR = 1.81) and in the highest quartile for aortic calcium (HR = 1.37) and decreased (p < .05) in patients in the highest quartile for VAT area (HR = 0.79) and SAT area (HR = 0.76). In 423 patients with available BMI, BMI did not significantly predict death (p = .75). CONCLUSION. Fully automated CT-based body composition measures including muscle attenuation, SAT area, and aortic calcium predict survival in patients with CRC. CLINICAL IMPACT. Routine pretreatment body composition evaluation could improve initial risk stratification of patients with CRC.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Lee, Pickhardt, Garrett, et al. Utility of Fully Automated Body Composition Measures on Pretreatment Abdominal CT for Predicting Survival in Patients With Colorectal Cancer. AJR Am J Roentgenol. 2022. PMID: 36000663. doi:10.2214/AJR.22.28043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。